Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants

Antiviral Research

Volumn 37, Issue 1, 1998, Pages 17-28

  Pelosi, Emanuela ^a,b   Mulamba, Gilbert B ^a   Coen, Donald M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

DNA polymerase; Latency; Neurovirulence; Thymidine kinase

Indexed keywords

ACICLOVIR; FOSCARNET; PENCICLOVIR; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HERPES; HERPES SIMPLEX VIRUS 1; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTANT;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CORNEA; DRUG RESISTANCE, MICROBIAL; GENES, POL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MUTATION; PHENOTYPE; PLAQUE ASSAY; THYMIDINE KINASE; TRIGEMINAL GANGLION; VERO CELLS; VIRULENCE; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALIA; DNA VIRUSES; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 0031984781     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(97)00054-5     Document Type: Article

References (60)

1. Boyd, M.R., Safrin, S., Kern, E.R., 1993. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. 4 (Suppl. 1), 3-11.
2. Chiou, H., 1988. PhD thesis, Harvard University.
3. Chiou, H., Weller, S.K., Coen, D.M., 1985. Mutations in the herpes simplex virus major DNA-binding protein gene leading to altered sensitivity to DNA polymerase inhibitors. Virology 145, 213-226.
4. Chiou, H.C., Kerns, K.M., Coen, D.M., 1986. Mutations within the herpes simplex virus DNA polymerase gene conferring resistance to (R)-9-(3,4-dihydroxybutyl)-guanine. Antimicrob. Agents Chemother. 30, 502-504.
5. Chiou, H.C., Kumura, K., Hu, A., Kerns, K.M., Coen, D.M., 1995. Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene. Antiviral Chem. Chemother. 6, 281-288.
6. Chrisp, C.E., Sunstrum, J.C., Averill, D.R. Jr., Levine, M., Glorioso, J.C., 1989. Characterization of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence. Lab. Invest. 60, 822-830.
7. Coen, D.M., 1992. Molecular aspects of anti-herpesvirus drugs. Sem. Virol. 3, 3-12.
8. Coen, D.M., 1994. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol. 2, 481-485.
9. Coen, D.M., 1996a. Antiviral drug resistance in herpes simplex virus. In: Mills, J.S., Corey, L. (Eds), Proc. Conf. Antiviral Chemotherapy, New Directions, pp. 49-57.
10. Coen, D.M., 1996b. Herpes simplex virus and varicella zoster virus: nucleosides and foscarnet. Mechanisms. In: Richman, D. (Ed), Antiviral Drug Resistance, Wiley, Chichester, pp. 81-102.
11. Coen, D.M., Schaffer, P.A., 1980. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc. Natl. Acad. Sci. USA 77, 2265-2269.
12. Coen, D.M., Dixon, R.A.F., Rub, S.W., Schaffe, P.A., 1980. Genetics of acycloguanosine resistance and the thymidine kinase gene in HSV-1. In: Fields, B., Jaenisch, R., Fox, C.F. (Eds.), Animal Virus Genetics, Academic Press, New York, pp. 581-590.
13. Coen, D.M., Furman, P.A., Gelep, P.T., Schaffer, P.A., 1982. Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine. J. Virol. 41, 909-918.
14. Coen, D.M., Fleming, H.E. Jr., Leslie, L.K., Retondo, M.J., 1985. Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus. J. Virol. 53, 477-488.
15. Coen, D.M., Weinheimer, S.P., McKnight, S.L., 1986. A genetic approach to promoter recognition during trans induction of viral gene expression. Science 234, 53-59.
16. Coen, D.M., Goldstein, D.J., Weller, S.K., 1989a. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother. 33, 1395-1399.
17. Coen, D.M., Irmiere, A.F., Jacobson, J.G., Kerns, K.M., 1989b. Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168, 221-231.
18. Coen, D.M., Kosz-Vnenchak, M., Jacobson, J.G., Leib, D.A., Bogard, C.L., Schaffer, P.A., Tyler, K.L., Knipe, D.M., 1989c. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA 86, 4736-4740.
19. Collins, P., Larder, B.A., Oliver, N.M., Kemp, S., Mith, I.W., DArby, G., 1989. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. J. Gen. Virol. 70, 375-382.
20. Darby, G., Churcher, M.J., Larder, B.A., 1984. Cooperative effects between two acyclovir resistance loci in herpes simplex virus. J. Virol. 50, 838-846.
21. Darby, G., Field, H.J., Salisbury, S.A., 1981. Altered substrate-specificity of herpes simplex virus thymidine kinase confers acyclovir resistance. Nature (Lond.) 289, 81-83.
22. Day, S.P., Lausch, R.N., Oakes, J.E., 1988. Evidence that the gene for herpes simplex virus type 1 DNA polymerase accounts for the capacity of an intertypic recombinant to spread from eye to central nervous system. Virology 163, 166-173.
23. Derse, D., Bastow, K.F., Cheng, Y., 1982. Characterization of the DNA polymerases induced by a group of herpes simplex virus type I variants selected for growth in the presence of phosphonoformic acid. J. Biol. Chem. 257, 10251-10260.
24. Efstathiou, S., Kemp, S., Darby, G., Minson, A.C., 1989. The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J. Gen. Virol. 70, 869-879.
25. Erlich, K.S., Mills, J., Chatis, P., Mertz, G.J., Busch, D., Follansbee, S.E., Grant, R.M., Crumpacker, C.S., 1989. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 320, 293-296.
26. Ertl, P., Snowden, W., Lowe, D., Miller, W., Littler, E., 1995. A comparative study of the in vitro and in vivo antiviral activities of aciclovir and penciclovir. Antiviral Chem. Chemother. 6, 89-97.
27. Field, H.J., Coen, D.M., 1986. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J. Virol. 60, 286-288.
28. Field, H.J., Darby, G., 1980. Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrob. Agents Chemother. 17, 209-216.
29. Field, H.J., Wildy, P., 1978. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. 81, 267-277.
30. Gibbs, J.S., Chiou, H.C., Bastow, K.F., Cheng, Y.C., Coen, D.M., 1988. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc. Natl. Acad. Sci. USA 85, 6672-6676.
31. Haarr, L., Marsden, H.S., Preston, C.M., Smiley, J.R., Summers, W.C., Summers, W.P., 1985. Utilization of internal AUG codons for initiation of protein synthesis directed by mRNAs from normal and mutant genes encoding herpes simplex virus-specified thymidine kinase. J. Virol. 56, 512-519.
32. Hannah, J., Tolman, R.L., Karkas, J.D., Liou, R., Perry, H.C., Field, A.K., 1989. Carba-acyclonucleoside antiherpetic agents. J. Heterocyclic Chem. 26, 1261-1271.
33. Irmiere, A.F., Manos, M.M., Jacobson, J.G., Gibbs, J.S., Coen, D.M., 1989. Effect of an amber mutation in the herpes simplex virus thymidine kinase gene on polypeptide synthesis and stability. Virology 168, 210-220.
34. Jacobson, J., Kramer, M., Rozenberg, F., Hu, A., Coen, D.M., 1995. Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. Virology 206, 263-268.
35. Jacobson, J.G., Ruffner, K.L., Kosz-Vnenchak, M., Hwang, C.B.C., Wobbe, K.K., Knipe, D.M., Coen, D.M., 1993. Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia. J. Virol. 67, 6903-6908.
36. Klein, R.J., Friedman-Kien, A.E., 1975. Phosphonoacetic acid-resistant herpes simplex virus infection in hairless mice. Antimicrob. Agents Chemother. 7, 289-293.
37. Klein, R.J., Friedman-Kien, A.E., DeStefano, E., 1981. Pathogenesis of experimental skin infections induced by drug resistant herpes simplex virus mutants. Infect. Immun. 34, 693-701.
38. Kost, R.G., Hill, E.G., Tigges, M., Straus, S.E., 1993. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N. Engl. J. Med. 329, 1777-1782.
39. Larder, B.A., Darby, G., 1984. Virus drug-resistance: mechanisms and consequences. Antiviral Res. 4, 1-42.
40. Larder, B.A., Darby, G., 1985. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. Virology 146, 262-271.
41. Larder, B.A., Kemp, S.D., Darby, G., 1987. Related functional domains in virus DNA polymerases. EMBO J. 6, 169-175.
42. Larder, B.A., Lisle, J.J., Darby, G., 1986. Restoration of wild-type pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type 1. J. Gen. Virol. 67, 2501-2506.
43. Lausch, R.N., Yeung, K.C., Miller, J.Z., Oakes, J.E., 1990. Nucleotide sequences responsible for the inability of a herpes simplex virus type 2 strain to grow in human lymphocytes are identical to those responsible for its inability to grow in mouse tissues following ocular infection. Virology 176, 319-328.
44. Leib, D.A., Coen, D.M., Bogard, C.L., Hicks, K.A., Yager, D.R., Knipe, D.M., Tyler, K.L., Schaffer, P.A., 1989. Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J. Virol. 63, 759-768.
45. Leib, D.A., Nadeau, K.C., Rundle, S.A., Schaffer, P.A., 1991. The promoter of the latency-associated transcripts of the herpes simplex virus type 1 contains a functional cAMP-raponse element: role of the latency-associated transcripts and cAMP in reactivation of viral latency. Proc. Natl. Acad. Sci. USA 88, 48-52.
46. Lowe, D.M., Alderton, W.K., Ellis, M.R., Parmar, V., Miller, W.H., Roberts, G.B., Fyfe, J.A., Gaillard, R., Ertl, P., Snowden, W., Littler, E., 1995. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother. 39, 1802-1808.
47. Marcy, A.I., Hwang, C.B., Ruffner, K.L., Coen, D.M., 1990. Engineered herpes simplex virus DNA polymerase point mutants: the most highly conserved region shared among alpha-like DNA polymerases is involved in substrate recognition. J. Virol. 64, 5883-5890.
48. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L., Coen, D.M., 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
49. Nugier, F., Collins, P., Larder, B.A., Langlois, M., Aymard, M., Darby, G., 1991. Herpes simplex virus isolates from an immunocompromised patient who failed to respond to acyclovir treatment express thymidine kinase with altered substrate specificity. Antiviral Chem. Chemother. 2, 295-302.
50. Reed, J.H., Muench, H., 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
51. Safrin, S., 1996. Herpes simplex virus and varicella zoster virus: nucleosides and foscarnet. Clinical aspects. In: Richman, D.D. (Ed), Antiviral Drug Resistance, Wiley, Chichester, pp. 103-122.
52. Safrin, S., Elbeik, T., Phan, L., Robinson, D., Rush, J., Elbaggari, A., Mills, J., 1994a. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 38, 1246-1250.
53. Safrin, S., Kemmerly, S., Plotkin, B., Smith, T., Weissbach, N., De Veranez, D., Phan, L.D., Cohn, D., 1994b. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis. 169, 193-196.
54. Sasadeusz, J.J., Tufaro, F., Safrin, S., Schubert, K., Hubinette, M.M., Cheung, P.K., Sacks, S.L., 1997. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J. Virol. 71, 3872-3878.
55. Smith, K.O., 1964. Relationships between the envelope and the infectivity of herpes simplex virus. Proc. Soc. Exp. Biol. Med. 115, 814-816.
56. Stevens, J.G., 1989. Human herpesviruses: a consideration of the latent state. Microbiol. Rev. 53, 318-332.
57. Summers, W.P., Summers, W.C., Laski, F.A., RajBhandary, U.L., Sharp, P.A., 1983. Functional suppression in mammalian cells of nonsense mutations in the herpes simplex virus thymidine kinase gene by suppressor tRNA genes. J. Virol. 47, 376-379.
58. Suzutani, T., Koyano, S., Takada, M., Yoshida, I., Azuma, M., 1995. Analysis of the relationship between cellular thymidine kinase activity and virulence of thymidine kinase-negative herpes simplex virus types 1 and 2. Microbiol. Immunol. 39, 787-794.
59. Tenser, R.B., 1983. Intracerebral inoculation of newborn and adult mice with thymidine kinase-deficient mutants of herpes simplex virus type 1. J. Infect. Dis. 147, 956.
60. Weller, S.K., Aschman, D.P., Sacks, W.R., Coen, D.M., Schaffer, P.A., 1983. Genetic analysis of temperature-sensitive mutants of HSV-1: the combined use of complementation and physical mapping for cistron assignment. Virology 130, 290-305.